ArticlePloS one2017
Mode of action of plectasin-derived peptides against gas gangrene-associated Clostridium perfringens type A.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 45 citations in OpenAlex.
- Natural and synthetic antimicrobial peptides against anaerobic bacteria: A review of activities and mechanisms of action.Probiotics and antimicrobial proteins · 2026Review
- Breaking the durability barrier with d band optimized Cu Fe twin crystal nanozymes for long term suppression of Botrytis cinerea.Nature communications · 2025Article
- Antimicrobial peptide plectasin recombinantly produced inJournal of bacteriology · 2025Article
- Inhibitory Effect of L-Methionine onJournal of fungi (Basel, Switzerland) · 2024Article
- A comparative evaluation of antibiotic and synbiotic supplementation on production performance and necrotic enteritis severity in broilers during an experimental necrotic enteritis challenge.Frontiers in physiology · 2024Article
- Foodborne Clostridioides Species: Pathogenicity, Virulence and Biocontrol Options.Microorganisms · 2023Review
- Mechanisms of aPharmaceutics · 2023Article
- Optimal Regimens and Clinical Breakpoint of Avilamycin AgainstFrontiers in pharmacology · 2022Article
- Protective Effects ofInternational journal of molecular sciences · 2021Article
- A study on fungal defensin against multidrug-resistant Clostridium perfringens and its treatment on infected poultry.Applied microbiology and biotechnology · 2021Article
- Fatty acid modified-antimicrobial peptide analogues with potent antimicrobial activity and topical therapeutic efficacy against Staphylococcus hyicus.Applied microbiology and biotechnology · 2021Article
- A recombinant fungal defensin-like peptide-P2 combats Streptococcus dysgalactiae and biofilms.Applied microbiology and biotechnology · 2021Article
- The Pharmacodynamics Study of Insect Defensin DLP4 Against ToxigenicFrontiers in cellular and infection microbiology · 2021Article
- Design and High Expression of Non-glycosylated Lysostaphins inFrontiers in microbiology · 2021Article
- Recombinant of the Staphylococcal Bacteriophage Lysin CHAPMicroorganisms · 2020Article
- Antimicrobial Susceptibility Testing of Antimicrobial Peptides to Better Predict Efficacy.Frontiers in cellular and infection microbiology · 2020Review
- Cell Membrane-Interrupting Antimicrobial Peptides fromBiomolecules · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
NZ2114 and MP1102 are novel plectasin-derived peptides with potent activity against Gram-positive bacteria. The antibacterial characteristics and mechanism of NZ2114 and MP1102 against gas gangrene-associated Clostridium perfringens were studied for the first time. The minimal inhibitory concentration and minimal bactericidal concentration of NZ2114 and MP1102 against resistant C. perfringens type A strain CVCC 46 were 0.91 μM. Based on the fractional inhibitory concentration index (FICI) result, an additive or synergic effect was observed between NZ2114 (FICI = 0.5~0.75) or MP1102 (FICI = 0.375~1.0) and antibiotics. The flow cytometry, scanning and transmission electron microscopy analysis showed that both NZ2114 and MP1102 induced obviously membrane damage, such as the leakage of cellular materials, partial disappearance of the cell membrane and membrane peeling, as well as retracting cytoplasm and ghost cell. The gel retardation and circular dichroism (CD) detection showed that NZ2114 and MP1102 could bind to C. perfringens genomic DNA and change the DNA conformation. Moreover, NZ2114 also interfered with the double helix and unwind the genomic DNA. The cell cycle analysis showed that C. perfringens CVCC 46 cells exposed to NZ2114 and MP1102 were arrested at the phase I. These data indicated that both NZ2114 and MP1102 have potential as new antimicrobial agents for gas gangrene infection resulting from resistant C. perfringens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.